The late filing of the annual report by TRxADE Health is a significant regulatory issue that directly impacts the company's standing with Nasdaq. Such events typically lead to negative investor sentiment due to concerns over governance and potential penalties. The direct mention of MEDS in relation to this issue makes it highly relevant and important for investors, with a high confidence level in the analysis due to the clear connection between regulatory compliance and stock performance.